Researchers evaluating safety and efficacy found that high-dose regimens carry a modest increase in the risk of hypotension compared to conventional low-dose treatments.
Clinical Efficacy in Sympathetic Crashing Acute Pulmonary Oedema
Patients treated with high-dose intravenous nitroglycerin experience fast improvements in blood pressure, respiratory rate, and oxygenation. The meta-analysis, led by Y.A. Jandali and colleagues, reviewed data from PubMed, Scopus, Web of Science, and the Cochrane Library up to March 2026. Investigators analyzed six studies encompassing 534 patients to compare high-dose strategies—defined as 100 micrograms per minute or greater, or equivalent bolus regimens—against conventional lower-dose protocols.
While symptom resolution reached 95% in single-arm analyses, high-dose therapy did not drastically alter hospital resource utilization. The data revealed no significant differences in intubation rates, which showed a risk ratio of 0.91 with a 95% confidence interval ranging from 0.11 to 7.73. Similarly, intensive care unit admission rates yielded a risk ratio of 0.92, spanning 0.81 to 1.05. Intensive care unit length of stay also showed no meaningful divergence, with a mean difference of minus 31.29 hours.
Hypotension Risk and Safety Profile
The primary trade-off identified in the 2026 meta-analysis involves an elevated vulnerability to low blood pressure. High-dose nitroglycerin administration was associated with a modest increase in the risk of hypotension, registering a risk ratio of 1.41 with a 95% confidence interval from 1.02 to 1.94. In single-arm evaluations, intensive care unit admission rates sat at 12%, while intubation rates hovered at 10%.
Did you know?
High-dose nitroglycerin produced numerically higher estimates for achieving target systolic blood pressure reductions than low-dose treatments, hitting a risk ratio of 1.70, though this trend did not reach statistical significance.
Authors of the study noted several limitations affecting the interpretation of these findings. Variations in how different trials defined low-dose comparators, discrepancies between specific high-dose regimens, and inconsistent reporting of co-interventions restricted the statistical power of the pooled data.
Frequently Asked Questions
What defines high-dose intravenous nitroglycerin in emergency settings?
Researchers define high-dose nitroglycerin as an infusion rate of 100 micrograms per minute or greater, or an equivalent bolus regimen.
Does high-dose nitroglycerin reduce the need for intubation?
Current evidence shows no statistically significant reduction in intubation rates or intensive care unit admissions when comparing high-dose strategies to conventional low-dose treatments.
What are the primary risks associated with high-dose nitroglycerin?
The analysis identified a modest increase in the risk of hypotension among patients receiving high-dose regimens.
Want to stay updated on the latest emergency medicine research and clinical meta-analyses?
Worth a look